GSK Moves Up US Filing Timeline For Triple Respiratory Combo
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to file a once-daily, closed triple combination containing a corticosteroid, a LABA and LAMA by the end of 2016, rather than the first half of 2018, as previously forecast.